Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Efsitora Weekly Insulin for Type 2 Diabetes

26 September 2026 · By · Wire by Fusion42

Published

26 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medpagetoday.com →

◆ Verified

Fusion42 · 26 September 2026 · Fusion42 review

The FDA has approved Efsitora (Onswik), a once-weekly basal insulin for adults with type 2 diabetes, marking it as the second weekly insulin option after insulin icodec. Clinical trials showed it to be as effective and safe as daily basal insulins while significantly reducing injection frequency.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 24 Sep 2026 and 26 Sep 2026.

◆ ◆ The Wire takeaway

You face a new standard in diabetes care with insulin dosing cut from daily to weekly. If you develop diabetes treatments, update your strategies to compete with Eli Lilly's easier-to-use weekly insulin.

◆ Coverage

5 sources · first reported 24 Sep 2026 · latest 26 Sep 2026

◆ Related on Wire

◆ Topics

Biotechtype-2-diabetesbasal-insulinfda-approvalweekly-dosingeli-lilly